Ontology highlight
ABSTRACT: Objective
We sought to evaluate whether 17 alpha-hydroxyprogesterone caproate (17-OHP) reduces preterm birth (PTB) in nulliparous women with a midtrimester cervical length (CL) <30 mm.Study design
In this multicenter randomized controlled trial, nulliparous women with a singleton gestation between 16 and 22 3/7 weeks with an endovaginal CL <30 mm (<10th percentile in this population) were randomized to weekly intramuscular 17-OHP (250 mg) or placebo through 36 weeks. The primary outcome was PTB <37 weeks.Results
The frequency of PTB did not differ between the 17-OHP (n = 327) and placebo (n = 330) groups (25.1% vs 24.2%; relative risk, 1.03; 95% confidence interval, 0.79-1.35). There also was no difference in the composite adverse neonatal outcome (7.0% vs 9.1%; relative risk, 0.77; 95% confidence interval, 0.46-1.30).Conclusion
Weekly 17-OHP does not reduce the frequency of PTB in nulliparous women with a midtrimester CL <30 mm.
SUBMITTER: Grobman WA
PROVIDER: S-EPMC3484249 | biostudies-literature | 2012 Nov
REPOSITORIES: biostudies-literature
Grobman William A WA Thom Elizabeth A EA Spong Catherine Y CY Iams Jay D JD Saade George R GR Mercer Brian M BM Tita Alan T N AT Rouse Dwight J DJ Sorokin Yoram Y Wapner Ronald J RJ Leveno Kenneth J KJ Blackwell Sean S Esplin M Sean MS Tolosa Jorge E JE Thorp John M JM Caritis Steve N SN Van Dorsten J Peter JP
American journal of obstetrics and gynecology 20120917 5
<h4>Objective</h4>We sought to evaluate whether 17 alpha-hydroxyprogesterone caproate (17-OHP) reduces preterm birth (PTB) in nulliparous women with a midtrimester cervical length (CL) <30 mm.<h4>Study design</h4>In this multicenter randomized controlled trial, nulliparous women with a singleton gestation between 16 and 22 3/7 weeks with an endovaginal CL <30 mm (<10th percentile in this population) were randomized to weekly intramuscular 17-OHP (250 mg) or placebo through 36 weeks. The primary ...[more]